[	(
Pulmonary	JJ
fibrosis	NN
--	:
a	DT
therapeutic	JJ
dilemma	NN
?	.

]	)
.	.

The	DT
idiopathic	JJ
interstitial	JJ
pneumonias	NNS
,	,
especially	RB
the	DT
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
,	,
are	VBP
life-threatening	JJ
lung	NN
disorders	NNS
,	,
for	IN
which	WDT
no	DT
effective	JJ
treatment	NN
option	NN
exists	VBZ
.	.

In	IN
view	NN
of	IN
IPF	NN
,	,
the	DT
American	NNP
Thoracic	NNP
Society	NNP
(	(
ATS	NNS
)	)
/	:
European	JJ
Respiratory	JJ
Society	NN
(	(
ERS	NNS
)	)
consensus	NN
statement	NN
recommends	VBZ
a	DT
combined	JJ
therapy	NN
with	IN
corticosteroids	NNS
and	CC
azathioprine	NN
or	CC
cyclophosphamide	NN
,	,
although	IN
data	NNS
from	IN
conclusive	JJ
clinical	JJ
trials	NNS
are	VBP
yet	RB
missing	VBG
and	CC
the	DT
recurrent	JJ
clinical	JJ
experience	NN
is	VBZ
that	IN
these	DT
drugs	NNS
do	VBP
not	RB
really	RB
help	VB
in	IN
IPF	NN
.	.

Up	IN
to	TO
now	RB
,	,
lung	NN
transplantation	NN
represents	VBZ
the	DT
last	JJ
and	CC
only	RB
therapeutic	JJ
option	NN
for	IN
IPF	NN
subjects	NNS
.	.

Based	VBN
on	IN
new	JJ
pathophysiological	JJ
concepts	NNS
of	IN
IPF	NN
,	,
there	EX
are	VBP
meanwhile	RB
a	DT
couple	NN
of	IN
different	JJ
agents	NNS
under	IN
preclinical	JJ
and	CC
clinical	JJ
assessment	NN
,	,
and	CC
the	DT
increasing	VBG
number	NN
of	IN
clinical	JJ
trials	NNS
ongoing	JJ
in	IN
IPF	NNP
raise	VB
the	DT
hope	NN
that	IN
an	DT
effective	JJ
treatment	NN
comes	VBZ
into	IN
reach	NN
.	.

The	DT
agents	NNS
investigated	VBN
and	CC
their	PRP$
targets	NNS
are	VBP
:	:
acetylcysteine	NN
(	(
reactive	JJ
oxygen	NN
species	NNS
[	(
ROS	NN
]	)
scavenging	NN
)	)
,	,
interferon-gamma	NN
1b	NN
(	(
modulation	NN
of	IN
Th1/Th2	NN
balance	NN
,	,
direct	JJ
antifibrotic	JJ
effects	NNS
)	)
,	,
pirfenidone	NN
and	CC
GC	NN
1008	CD
(	(
blockade	NN
of	IN
transforming-growth-factor-beta	NN
)	)
,	,
FG	NN
3019	CD
(	(
blockade	NN
of	IN
connective-tissue-growth-factor	NN
)	)
,	,
imatinib	NN
mesylate	NN
(	(
blockade	NN
of	IN
platelet-derived	JJ
growth	NN
factor	NN
)	)
,	,
bosentan	NN
(	(
blockade	NN
of	IN
endothelin	NN
)	)
,	,
zileutin	NN
(	(
blockade	NN
of	IN
leukotrienes	NNS
)	)
,	,
etanercept	NN
(	(
blockade	NN
of	IN
tumor-necrosis-factor-alpha	NN
)	)
,	,
heparin	NN
(	(
alveolar	JJ
anticoagulation	NN
)	)
.	.

Hopefully	RB
,	,
these	DT
new	JJ
therapeutic	JJ
strategies	NNS
may	MD
help	VB
to	TO
improve	VB
prognosis	NN
of	IN
IPF	NN
in	IN
the	DT
future	NN
.	.

